Form 4: Keros Therapeutics Director Alpna Seth Receives Equity Grant

Director Alpna Seth acquired 7,142 restricted stock units and 7,433 stock options in Keros Therapeutics, Inc.

Summary

• Director Alpna Seth was granted 7,142 restricted stock units (RSUs) on June 3, 2026.
• The director also received a stock option grant for 7,433 shares with an exercise price of $10.50.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 12,392 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized vesting schedules ensure long-term commitment from the director.

Negatives

• The issuance of new equity results in minor dilution for existing shareholders.

Risks

• Future share price volatility may impact the value of the granted options.
• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The RSUs are scheduled to vest on the earlier of June 3, 2027, or the 2027 annual meeting of stockholders. The stock options vest in equal quarterly installments over 12 months, fully vesting by the 2027 annual meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level expertise for corporate governance.

Comparison to Industry Standards

• The use of RSU and option combinations is consistent with compensation structures for directors in mid-cap biotech firms.
• Vesting periods aligned with annual meetings are standard governance practice to ensure board continuity.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of RSUs on June 3, 2027, or the 2027 annual meeting.
• Quarterly vesting of stock options over the next 12 months.

Key Dates

Keywords

Keros Therapeutics, KROS, Form 4, Insider Trading, Equity Compensation, Director Compensation